文献速递前列腺癌

新诊断前列腺癌主动监测进展者的整合基因组分析

Integrative Genomic Profiling of Newly Diagnosed Prostate Cancers Progressing on Surveillance.
PubMed 文献 · Urology · 2026-06-24

该回顾性试点研究对7例低至中危前列腺癌患者进行序列mpMRI靶向活检,采用激光捕获显微切割分离组织成分后行外显子组和转录组测序。

要点

  • 克隆复杂性≥3个亚克隆与主动监测中更早进展至确定性治疗相关。
  • 序列mpMRI靶向活检可因采样不同克隆而呈现不一致的体细胞谱。
  • 单个基因级改变或少数染色体大事件未显示与至治疗时间相关。

核心结论

  • 在该小型假设生成队列中,克隆复杂性比单个基因组改变与更早的确定性治疗相关性更强。

研究设计与样本

  • 回顾性试点研究纳入7例低至中危前列腺癌患者,均接受主动监测并最终行确定性治疗。
  • 对序列mpMRI靶向活检的同一病灶标本行激光捕获显微切割分离肿瘤上皮、良性腺体、高级别前列腺上皮内瘤变和间质。
  • 肿瘤与配对良性组织DNA行全外显子组测序,所有组分RNA行全转录组测序。

主要发现

  • 肿瘤表现出显著瘤内异质性,6对配对病例中3例的序列mpMRI靶向活检显示不一致的体细胞谱,符合随时间采样到不同主要克隆。
  • 无单个基因级改变与至治疗时间相关,且少数染色体大事件与至治疗时间相关。
  • 对个别组织成分的探索性通路分析提示至治疗时间相关差异涉及炎症信号和间质-上皮交互。

临床怎么用

  • 多组学克隆结构测量可能改善主动监测风险分层,但需更大前瞻性研究验证。

局限性

  • 样本量小(7例),为假设生成性试点研究,结论需更大前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To identify molecular features associated with earlier progression to definitive therapy amongst patients with localized prostate cancer (PCa) managed on active surveillance (AS). METHODS: We performed a retrospective pilot study of 7 patients with low- to intermediate-risk PCa undergoing serial multiparametric MRI (mpMRI)-targeted biopsies of the same lesion while on AS, who all proceeded to definitive therapy. Time-to-treatment (TTT) was defined as years from first biopsy on AS to definitive therapy. Laser-capture microdissection was used to separate tumor epithelium, benign glands, high-grade prostatic intraepithelial neoplasia, and stroma in each biopsy specimen. DNA from the tumor and matched benign tissue underwent whole-exome sequencing, and RNA from all compartments underwent whole-transcriptome sequencing. Somatic mutations and copy-number alterations were compared across serial biopsies and used to reconstruct phylogenies and quantify clonal complexity. RESULTS: Tumors exhibited substantial intratumoral heterogeneity, and in 3 of 6 paired cases, serial mpMRI-targeted biopsies showed discordant somatic profiles consistent with sampling distinct major clones over time. By contrast, no single gene-level alteration, and few large-scale chromosomal events, were associated with TTT. High clonal complexity, defined as ≥3 subclones, was associated with significantly shorter TTT than low complexity (median 1.9 vs 7.2 years; P = .0082). Exploratory pathway analyses of individual tissue components suggested TTT-associated differences in inflammatory signaling and stromal-epithelial cross-talk. CONCLUSION: In this small, hypothesis-generating cohort, clonal complexity was more closely associated with earlier definitive therapy than individual genomic alterations. Larger prospective studies are needed to validate whether multiomic measures of clonal architecture can improve AS risk stratification.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Whitlock NC, Silver R, Trostel SY, et al. Integrative Genomic Profiling of Newly Diagnosed Prostate Cancers Progressing on Surveillance. Urology. 2026. PMID: 42341949. doi:10.1016/j.urology.2026.06.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。